New insights into the mode of action of the lantibiotic salivaricin B

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Barbour, Abdelahhad ^a   Tagg, John ^b   Abou Zied, Osama K ^c   Philip, Koshy ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; BACTERIOCIN; SALIVARICIN A;

AMINO ACID SEQUENCE; CELL WALL; CHEMISTRY; DRUG EFFECT; GRAM POSITIVE BACTERIUM; MICROBIAL SENSITIVITY TEST; MICROCOCCUS LUTEUS; STREPTOCOCCUS PYOGENES; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIOCINS; CELL WALL; GRAM-POSITIVE BACTERIA; MICROBIAL SENSITIVITY TESTS; MICROCOCCUS LUTEUS; MICROSCOPY, ELECTRON, TRANSMISSION; STREPTOCOCCUS PYOGENES;

EID: 84982218406     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep31749     Document Type: Article

References (62)

1. Bierbaum, G., Sahl, H. G. Lantibiotics: mode of action, biosynthesis and bioengineering. Curr. Pharm. Biotechnol. 10, 2-18 (2009).
2. Jack, R. W., Tagg, J. R., Ray, B. Bacteriocins of gram-positive bacteria. Microbiol. Rev. 59, 171-200 (1995).
3. Völler, G. H. et al. Characterization of new class III lantibiotics-erythreapeptin, avermipeptin and griseopeptin from Saccharopolyspora erythraea, Streptomyces avermitilis and Streptomyces griseus demonstrates stepwise N-terminal leader processing. ChemBioChem. 13, 1174-1183, doi: 10.1002/cbic.201200118 (2012).
4. Kodani, S. et al. The SapB morphogen is a lantibiotic-like peptide derived from the product of the developmental gene ramS in Streptomyces coelicolor. PNAS 101, 11448-11453, doi: 10.1073/pnas.0404220101 (2004).
5. Rogers, L. A., Whittier, E. O. Limiting factors in the lactic fermentat. J. Bacteriol. 16, 211-229 (1928).
6. Delves-Broughton, J., Blackburn, P., Evans, R. J., Hugenholtz, J. Applications of the bacteriocin, nisin. Antonie Van Leeuwenhoek 69, 193-202 (1996).
7. Brötz, H., Sahl, H.-G. New insights into the mechanism of action of lantibiotics-diverse biological effects by binding to the same molecular target. J. Antimicrob. Chemother. 46, 1-6, doi: 10.1093/jac/46.1.1 (2000).
8. Moll, G., Konings, W., Driessen, A. M. In Lactic Acid Bacteria Vol. 98 NATO ASI Series (eds T. Faruk Bozolu & Bibek, Ray) Ch. 14, 327-345 (Springer Berlin Heidelberg, 1996).
9. Brotz, H., Bierbaum, G., Markus, A., Molitor, E., Sahl, H. G. Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism J. Antimicrob. Chemother. 39, 714-719 (1995).
10. Brotz, H., Bierbaum, G., Leopold, K., Reynolds, P. E., Sahl, H. G. The lantibiotic mersacidin inhibits peptidoglycan synthesis by targeting lipid II. J. Antimicrob. Chemother. 42, 154-160 (1998).
11. Hsu, S. T. et al. NMR study of mersacidin and lipid II interaction in dodecylphosphocholine micelles. Conformational changes are a key to antimicrobial activity. J. Biol. Chem. 278, 13110-13117, doi: 10.1074/jbc.M211144200 (2003).
12. Bottiger, T., Schneider, T., Martinez, B., Sahl, H. G., Wiedemann, I. Influence of Ca(2+ ) ions on the activity of lantibiotics containing a mersacidin-like lipid II binding motif. Appl. Environ. Microbiol. 75, 4427-4434, doi: 10.1128/AEM.00262-09 (2009).
13. Altena, K., Guder, A., Cramer, C., Bierbaum, G. Biosynthesis of the lantibiotic mersacidin: organization of a type B lantibiotic gene cluster. Appl. Environ. Microbiol. 66, 2565-2571 (2000).
14. Sahl, H. G., Jack, R. W., Bierbaum, G. Biosynthesis and biological activities of lantibiotics with unique post-translational modifications. Eur. J. Biochem. 230, 827-853 (1995).
15. Uguen, P., Le Pennec, J.-P., Dufour, A. Lantibiotic Biosynthesis: Interactions between prelacticin 481 and Its putative modification enzyme, LctM. J. Bacteriol. 182, 5262-5266, doi: 10.1128/jb.182.18.5262-5266.2000 (2000).
16. Dufour, A., Hindre, T., Haras, D., Le Pennec, J. P. The biology of lantibiotics from the lacticin 481 group is coming of age. FEMS Microbiol. Rev. 31, 134-167, doi: 10.1111/j.1574-6976.2006.00045.x (2007).
17. Bravo, D., Rodriguez, E., Medina, M. Nisin and lacticin 481 coproduction by Lactococcus lactis strains isolated from raw ewes' milk. J. Dairy Sci. 92, 4805-4811, doi: 10.3168/jds.2009-2237 (2009).
18. Hyink, O. et al. Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl. Environ. Microbiol. 73, 1107-1113, doi: 10.1128/AEM.02265-06 (2007).
19. Wescombe, P. A., Hale, J. D., Heng, N. C., Tagg, J. R. Developing oral probiotics from Streptococcus salivarius. Future Microbiol. 7, 1355-1371, doi: 10.2217/fmb.12.113 (2012).
20. Wescombe, P. A. et al. Production of the lantibiotic salivaricin A and its variants by oral streptococci and use of a specific induction assay to detect their presence in human saliva. Appl. Environ. Microbiol. 72, 1459-1466, doi: 10.1128/AEM.72.2.1459-1466.2006 (2006).
21. Wescombe, P. A. et al. Salivaricin G32, a homolog of the prototype Streptococcus pyogenes nisin-like lantibiotic SA-FF22, produced by the commensal species Streptococcus salivarius. Int. J. Microbiol. 2012, 738503, doi: 10.1155/2012/738503 (2012).
22. Wescombe, P. A. et al. Salivaricin 9, a new lantibiotic produced by Streptococcus salivarius. Microbiology 157, 1290-1299, doi: 10.1099/mic.0.044719-0 (2011).
23. Barbour, A., Philip, K., Muniandy, S. Enhanced production, purification, characterization and mechanism of action of salivaricin 9 lantibiotic produced by Streptococcus salivarius NU10. PLoS One 8, e77751, doi: 10.1371/journal.pone.0077751 (2013).
24. Barbour, A., Philip, K. Variable characteristics of bacteriocin-producing Streptococcus salivarius strains isolated from Malaysian subjects. PLoS One 9, e100541, doi: 10.1371/journal.pone.0100541 (2014).
25. Tagg, J. R., Bannister, L. V. "Fingerprinting" beta-haemolytic streptococci by their production of and sensitivity to bacteriocine-like inhibitors. J. Med. Microbiol. 12, 397-411 (1979).
26. Knerr, P. J. et al. Non-proteinogenic amino acids in lacticin 481 analogues result in more potent inhibition of peptidoglycan transglycosylation. ACS Chem. Biol. 7, 1791-1795, doi: 10.1021/cb300372b (2012).
27. Idayu Zahid, N., Abou-Zied, O. K., Hashim, R., Heidelberg, T. Characterization of the head group and the hydrophobic regions of a glycolipid lyotropic hexagonal phase using fluorescent probes. J. Phys. Chem. C 115, 19805-19810, doi: 10.1021/jp2060393 (2011).
28. Lakowicz, J. R. Principles of fluorescence spectroscopy, 3rd ed. Springer Science: New York (2006.).
29. Nichols, M. et al. Dynamic turn conformation of a short tryptophan-rich cationic antimicrobial peptide and its interaction with phospholipid membranes. J. Phys. Chem. B 117, 14697-14708, doi: 10.1021/jp4096985 (2013).
30. Abou-Zied, O. K., Barbour, A., Al-Sharji, N. A., Philip, K. Elucidating the mechanism of peptide interaction with membranes using the intrinsic fluorescence of tryptophan: perpendicular penetration of cecropin B-like peptides into Pseudomonas aeruginosa. RSC Adv. 5, 14214-14220, doi: 10.1039/c4ra15246h (2015).
31. Wiedemann, I., Benz, R., Sahl, H.-G. Lipid II-mediated pore formation by the peptide antibiotic nisin: a black lipid membrane study. J. Bacteriol. 186, 3259-3261, doi: 10.1128/jb.186.10.3259-3261.2004 (2004).
32. Christ, K., Wiedemann, I., Bakowsky, U., Sahl, H.-G., Bendas, G. The role of lipid II in membrane binding of and pore formation by nisin analyzed by two combined biosensor techniques. Biochim. Biophys. Acta 1768, 694-704 (2007).
33. Ruhr, E., Sahl, H. G. Mode of action of the peptide antibiotic nisin and influence on the membrane potential of whole cells and on cytoplasmic and artificial membrane vesicles. J. Antimicrob. Chemother. 27, 841-845 (1985).
34. Moll, G. N., Roberts, G. C., Konings, W. N., Driessen, A. J. Mechanism of lantibiotic-induced pore-formation. Antonie van Leeuwenhoek 69, 185-191 (1996).
35. van Kraaij, C. et al. Pore formation by nisin involves translocation of its C-terminal part across the membrane. Biochemistry 37, 16033-16040, doi: 10.1021/bi980931b (1998).
36. Wiedemann, I. et al. Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J. Biol. Chem. 276, 1772-1779, doi: 10.1074/jbc.M006770200 (2001).
37. Wiedemann, I. et al. The mode of action of the lantibiotic lacticin 3147-a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Mol. Microbiol. 61, 285-296, doi: 10.1111/j.1365-2958.2006.05223.x (2006).
38. Asaduzzaman, S. M. et al. Nukacin ISK-1, a bacteriostatic lantibiotic. J. Antimicrob. Chemother. 53, 3595-3598, doi: 10.1128/AAC.01623-08 (2009).
39. Roy, U. et al. Bactericidal activity of nukacin ISK-1: an alternative mode of action. Biosci. Biotechnol. Biochem 78, 1270-1273, doi: 10.1080/09168451.2014.918485 (2014).
40. Chikindas, M. L. et al. Mutacin II, a bactericidal antibiotic from Streptococcus mutans. J. Antimicrob. Chemother. 39, 2656-2660, doi: 10.1128/aac.39.12.2656 (1995).
41. Jack, R., Benz, R., Tagg, J., Sahl, H. G. The mode of action of SA-FF22, a lantibiotic isolated from Streptococcus pyogenes strain FF22. Eur. J. Biochem. 219, 699-705 (1994).
42. Hyde, A. J., Parisot, J., McNichol, A., Bonev, B. B. Nisin-induced changes in Bacillus morphology suggest a paradigm of antibiotic action. PNAS 103, 19896-19901, doi: 10.1073/pnas.0608373104 (2006).
43. Breukink, E. et al. Use of the cell wall precursor lipid II by a pore-forming peptide antibiotic. Science 286, 2361-2364, doi: 10.1126/science.286.5448.2361 (1999).
44. Bonev, B. B., Breukink, E., Swiezewska, E., De kruijff, B., Watts, A. Targeting extracellular pyrophosphates underpins the high selectivity of nisin. The FASEB Journal 18, 1862-1869, doi: 10.1096/fj.04-2358com (2004).
45. Schved, F., Henis, Y., Juven, B. J. Response of spheroplasts and chelator-permeabilized cells of gram-negative bacteria to the action of the bacteriocins pediocin Sj-1 and nisin. Int J Food Microbiol 21, 305-314, doi: Doi 10.1016/0168-1605(94)90060-4 (1994).
46. Schved, F., Pierson, M. D., Juven, B. J. Sensitization of Escherichia coli to nisin by maltol and ethyl maltol. Lett Appl Microbiol 22, 189-191, doi: DOI 10.1111/j.1472-765X.1996.tb01139.x (1996).
47. Reynolds, P. E. Studies on the mode of action of vancomycin. Biochim. Biophys. Acta 52, 403-405, doi: http://dx.doi. org/10.1016/0006-3002(61)90698-9 (1961).
48. Siewert, G., Strominger, J. L. Bacitracin: an inhibitor of the dephosphorylation of lipid pyrophosphate, an intermediate in the biosynthesis of the peptidoglycan of bacterial cell walls. PNAS 57, 767-773 (1967).
49. Somner, E. A., Reynolds, P. E. Inhibition of peptidoglycan biosynthesis by ramoplanin. J. Antimicrob. Chemother. 34, 413-419 (1990).
50. Brötz, H., Bierbaum, G., Reynolds, P. E., Sahl, H.-G. The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. Eur. J. Biochem. 246, 193-199, doi: 10.1111/j.1432-1033.1997.t01-1-00193.x (1997).
51. Islam, M. R. et al. Ring A of nukacin ISK-1: a lipid II-binding motif for type-A(II) lantibiotic. J. Am. Chem. Soc. 134, 3687-3690, doi: 10.1021/ja300007h (2012).
52. Draper, L. A., Cotter, P. D., Hill, C., Ross, R. P. Lantibiotic resistance. Microbiol. Mol. Biol. Rev. 79, 171-191, doi: 10.1128/MMBR.00051-14 (2015).
53. Kramer, N. E. et al. Resistance of Gram-positive bacteria to nisin is not determined by Lipid II levels. FEMS Microbiol Lett. 239, 157-161, doi: 10.1016/j.femsle.2004.08.033 (2004).
54. Khosa, S. et al. Structural basis of lantibiotic recognition by the nisin resistance protein from Streptococcus agalactiae. Sci. Rep. 6, 18679, doi: 10.1038/srep18679 (2016).
55. Draper, L. A., Tagg, J. R., Hill, C., Cotter, P. D., Ross, R. P. The spiFEG Locus in Streptococcus infantarius subsp. infantarius BAA-102 Confers Protection against Nisin U. J. Antimicrob. Chemother. 56, 573-578, doi: 10.1128/aac.05778-11 (2012).
56. Masdea, L. et al. Antimicrobial activity of Streptococcus salivarius K12 on bacteria involved in oral malodour. Arch Oral Biol 57, 1041-1047, doi: 10.1016/j.archoralbio.2012.02.011 (2012).
57. Brumfitt, W., Salton, M. R. J., Hamilton-Miller, J. M. T. Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. J. Antimicrob. Chemother. 50, 731-734, doi: 10.1093/jac/dkf190 (2002).
58. Abts, A. et al. Easy and rapid purification of highly active nisin. Int J Pept 2011, 175145, doi: 10.1155/2011/175145 (2011).
59. Bourbon, C. et al. Use of a real-time polymerase chain reaction thermocycler to study bacterial cell permeabilization by antimicrobial peptides. Anal. Biochem. 381, 279-281, doi: 10.1016/j.ab.2008.07.005 (2008).
60. Wilmes, M. et al. Killing of Staphylococci by-defensins involves membrane impairment and activation of autolytic enzymes. J. Antibiot. 3, 617 (2014).
61. Schmitt, P. et al. Insight into invertebrate defensin mechanism of action: Oyster defensins inhibit peptidoglycan biosynthesis by binding to lipid II. J. Biol. Chem. 285, 29208-29216, doi: 10.1074/jbc.M110.143388 (2010).
62. Sass, V. et al. Human-defensin 3 inhibits cell wall biosynthesis in Staphylococci. Infect. Immun. 78, 2793-2800, doi: 10.1128/iai.00688-09 (2010).